The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study

RECOMMENDED

Asthma

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

J Allergy Clin Immunol.

Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H

doi: 10.1016/j.jaci.2018.09.033.

RECOMMENDED

Asthma

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Busse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, Deniz Y, Patel N, Harel S, Rowe PJ, Graham NMH, O'Riordan T, Pavord ID

doi: 10.1016/S2213-2600(21)00124-7

Asthma

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma

Biologics

Haldar P

doi: 10.2147/BTT.S93954.

RECOMMENDED

Asthma

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

J Asthma Allergy

Prazma CM, Idzko M, Douglass JA, Bourdin A, Mallett S, Albers FC, Yancey SW

doi: 10.2147/JAA.S298559

Asthma

Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study

J Asthma.

Albers FC, Müllerová H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, Cockle SM, Suruki RY

doi: 10.1080/02770903.

Asthma

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

Lancet Respir Med.

Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A

doi: 10.1016/

RECOMMENDED

Asthma

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA

Respir Res.

Albers FC, Papi A, Taillé C, Bratton DJ, Bradford ES, Yancey SW, Kwon N

doi: 10.1186/s12931-019-1134-7.

Asthma

The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies

Curr Med Res Opin.

Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X

doi: 10.1080/

RECOMMENDED

Asthma

Identification and prospective stability of eNose derived inflammatory phenotypes in severe asthma

J Allergy Clin Immunol.

Brinkman P, Wagener AH, Hekking PP, Bansal AT, Maitland-van der Zee AH, Wang Y, Weda H, Knobel HH, Vink TJ, Rattray NJ, D'Amico A, Pennazza G, Santonico M, Lefaudeux D, De Meulder B, Auffray C, Bakke PS, Caruso M, Chanez P, Chung KF, Corfield J, Dahlén SE, Djukanovic R, Geiser T, Horvath I, Krug N, Musial J, Sun K, Riley JH, Shaw DE, Sandström T, Sousa AR, Montuschi P, Fowler SJ, Sterk PJ; U-BIOPRED Study Group

doi: 10.1016/j.jaci.2018.10.058.

Related content

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes

Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA

The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies

Identification and prospective stability of eNose derived inflammatory phenotypes in severe asthma